Fig. 5: ABHD11 inhibition impairs CD4+ T-cell function in autoimmunity.
From: Mitochondrial ABHD11 inhibition drives sterol metabolism to modulate T-cell effector function
a Experimental design of rheumatoid arthritis (RA) and type 1 diabetes (T1D) patient cohorts. b, c IL-2, IL-10, IL-17, IFNγ and TNFα production by patient-derived CD4+ T-cells from (b) RA (n = 7) and c T1D (n = 8) cohorts. d, e Surface expression of activation markers (CD25, CD44 and CD69) on patient-derived CD4 + T-cells from (d) RA (n = 7) and e T1D (n = 8) cohorts. f Experimental design of RA patient synovial fluid mononuclear cells (SFMCs). g IL-2, IL-10, IL-17, IFNγ and TNFα production by patient-derived SFMCs (n = 5). (h) Surface expression of activation markers (CD25, CD44 and CD69) on patient-derived SFMCs (n = 5). All experiments were carried out using human samples. CD4+ T-cells were activated with α-CD3 (2 μg/ml) and α-CD28 (20 μg/ml) for 24 h, in the presence and absence of ML-226, unless otherwise stated. Data are expressed as mean, with paired dots representing data from distinct biological replicates. Statistical tests used: two-tailed paired t-test (b–e, g, h). Source data are provided as a Source Data file.
